Acorda Therapeutics Inc. (ACOR) and Alector Inc. (NASDAQ:ALEC) Comparing side by side – MS Wkly

Posted: Published on October 18th, 2019

This post was added by Alex Diaz-Granados

Both Acorda Therapeutics Inc. (NASDAQ:ACOR) and Alector Inc. (NASDAQ:ALEC) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Earnings and Valuation

In table 1 we can see Acorda Therapeutics Inc. and Alector Inc.s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 represents Acorda Therapeutics Inc. (NASDAQ:ACOR) and Alector Inc. (NASDAQ:ALEC)s return on assets, return on equity and net margins.

Liquidity

The current Quick Ratio of Acorda Therapeutics Inc. is 4 while its Current Ratio is 4.3. Meanwhile, Alector Inc. has a Current Ratio of 7.9 while its Quick Ratio is 7.9. Alector Inc. is better positioned to pay off its short-term and long-term debts than Acorda Therapeutics Inc.

Analyst Recommendations

Recommendations and Ratings for Acorda Therapeutics Inc. and Alector Inc. can be find in next table.

Acorda Therapeutics Inc. has a 158.53% upside potential and a consensus price target of $6.67.

Insider and Institutional Ownership

Roughly 0% of Acorda Therapeutics Inc. shares are held by institutional investors while 59.1% of Alector Inc. are owned by institutional investors. 1.5% are Acorda Therapeutics Inc.s share held by insiders. Competitively, insiders own roughly 8.1% of Alector Inc.s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Acorda Therapeutics Inc. has -55.52% weaker performance while Alector Inc. has 17.33% stronger performance.

Summary

Alector Inc. beats on 6 of the 11 factors Acorda Therapeutics Inc.

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops CVT-301 that has completed a Phase III clinical trial for the treatment of OFF periods in Parkinsons disease; CVT-427, which has completed a Phase I clinical trial to treat migraine; Tozadenant that is in Phase III clinical trial for reduction of OFF time in Parkinsons disease; SYN120, which is in Phase II clinical trial to treat Parkinsons disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; Cimaglermin alfa that has completed a Phase I clinical trial in heart failure patients; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; SK Biopharmaceuticals Co., Ltd.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Cambridge Enterprise Limited and King's College London; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Womens Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read the rest here:
Acorda Therapeutics Inc. (ACOR) and Alector Inc. (NASDAQ:ALEC) Comparing side by side - MS Wkly

Related Posts
This entry was posted in Spinal Cord Injury Treatment. Bookmark the permalink.

Comments are closed.